RxDoctor Payments Data

Douglas Woseth, MD

Dermatology · Salt Lake, UTNPI 1619978970

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $25,369 of the $33,287 with a category attached, or 76.2%. Incyte Corporation accounts for 84.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $16,817 and has fallen 95.4% since, to $779 in 2025. Among dermatology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,287in general payments, 2019–2025

Across 390 payments — averaging $85.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$28K
  • AbbVie$1K
  • Johnson & Johnson$655
  • Pfizer$602
  • Novartis$554
  • UCB, Inc.$391
  • plus $2K from 21 others
$432,471in research payments, 2019–2025

Across 81 payments — averaging $5339.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$329K
  • Eli Lilly$41K
  • Galderma Laboratories, L.p.$37K
  • Teva Pharmaceuticals USA, Inc.$19K
  • Sun Pharmaceutical Industries Inc.$7K

What the payments were for

  • Speaking & faculty fees$25,36976%
  • Travel & lodging$1,9586%
  • Food & beverage$5,58617%
  • Education$3741%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,287 in reported general payments places this provider in the 90th percentile of 163 dermatology providers in Utah.

See all dermatology providers in Utah

Medicare billing

Part B allowed, 2024
$235,624
Medicare patients
642
Services billed
2,855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol Propionate84$2,750
Doxycycline Hyclate15$2,722
Fluorouracil33$2,540
Triamcinolone Acetonide127$1,508
Clindamycin Phosphate27$1,480
Metronidazole22$781
ValacyclovirValacyclovir Hcl35$600
Ketoconazole29$410
Mupirocin38$320
Minoxidil20$293
Cephalexin24$224

Paid to pharmacies, not to this prescriber.

Other dermatology in Salt Lake

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →